Oppenheimer Maintains a 'Perform' on Integra LifeSciences (IART); Meeting with CEO
Tweet Send to a FriendGet Alerts IART Hot Sheet
Price: $36.94 -0.05%
Rating Summary:
8 Buy, 9 Hold, 1 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 13 | Down: 25 | New: 24
Rating Summary:
8 Buy, 9 Hold, 1 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 13 | Down: 25 | New: 24
Trade IART Now!
Oppenheimer maintains a 'Perform' on Integra LifeSciences (NASDAQ: IART) price target of $46.00 (from $42.00).
Analyst, Steven Lichtman, said, "During our recent day on the road with IART, CEO Peter Arduini focused on the three key near-term priorities: execution, optimization, and growth acceleration. Looking forward, with an enhanced executive team in place, IART will focus on a more disciplined approach to R&D, meaningful leverage opportunities (particularly in COGS), and international expansion. We expect the stock to continue to push higher into the company's October 24 analyst day where management is expected to lay out more details on its cost saving plans. On an increased long-term operating margin assumption, we raise our price target to $46."
FY13 EPS estimate lowered from $3.20 to $3.17.
For an analyst ratings summary and ratings history on Integra LifeSciences click here. For more ratings news on Integra LifeSciences click here.
Shares of Integra LifeSciences closed at $40.63 yesterday, with a 52 week range of $23.09-$41.09.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
Analyst, Steven Lichtman, said, "During our recent day on the road with IART, CEO Peter Arduini focused on the three key near-term priorities: execution, optimization, and growth acceleration. Looking forward, with an enhanced executive team in place, IART will focus on a more disciplined approach to R&D, meaningful leverage opportunities (particularly in COGS), and international expansion. We expect the stock to continue to push higher into the company's October 24 analyst day where management is expected to lay out more details on its cost saving plans. On an increased long-term operating margin assumption, we raise our price target to $46."
FY13 EPS estimate lowered from $3.20 to $3.17.
For an analyst ratings summary and ratings history on Integra LifeSciences click here. For more ratings news on Integra LifeSciences click here.
Shares of Integra LifeSciences closed at $40.63 yesterday, with a 52 week range of $23.09-$41.09.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- UPDATE: UBS Downgrades Carnival (CCL) to Neutral; Worst May Not Be Behind
- Jefferies Bumps PT/Est. on AO Smith (AOS)
- First Time Cruisers Pass on Carnival (CCL); Wells Fargo Cuts to Market Perform
Create E-mail Alert Related Categories
Analyst Comments, Analyst EPS Change, Analyst EPS View, Analyst PT Change
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
